Camrelizumab/lenvatinibHypertension: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1953卷 / 1期

关键词：

D O I：

10.1007/s40278-023-37553-3

中图分类号：

学科分类号：

摘要：

引用

下载

收藏

页码：118 / 118

相关论文

共 50 条

[1] Camrelizumab/lenvatinibHypertension and hypothyroidism: 2 case reports
Reactions Weekly, 2024, 2035 (1) : 126 - 126
[2] LenvatinibHypertension: case report
Reactions Weekly, 2019, 1776 (1) : 261 - 261
[3] LenvatinibHypertension and renal disorders with complications: case report
Reactions Weekly, 2018, 1728 (1) : 211 - 211
[4] LenvatinibHypertension and drug induced colitis: case report
Reactions Weekly, 2021, 1847 (1) : 271 - 271
[5] LenvatinibHypertension and renal limited thrombotic microangiopathy: case report
Reactions Weekly, 2024, 2028 (1) : 271 - 271
[6] Camrelizumab/rivoceranibHypothyroidism: case report
Reactions Weekly, 2023, 1952 (1) : 111 - 111
[7] Iodine-radioactive/lenvatinibHypertension and lack of efficacy: case report
Reactions Weekly, 2021, 1837 (1) : 360 - 360
[8] Camrelizumab/lenvatinibHepatic failure: case report
Reactions Weekly, 2022, 1929 (1) : 164 - 164
[9] Camrelizumab/rivoceranibLack of efficacy: case report
Reactions Weekly, 2023, 1981 (1) : 105 - 105
[10] Camrelizumab/catequentinibVarious toxicities: case report
Reactions Weekly, 2023, 1951 (1) : 96 - 96

← 1 2 3 4 5 →